MDPI has acquired Current Oncology, Canada's premier oncology journal, with plans to enhance its global presence and influence in the cancer research field.
Target Information
MDPI has successfully acquired Current Oncology, the leading oncology journal in Canada, from Multimed Inc. Established in 1994, Current Oncology was the first peer-reviewed journal in oncology in Canada, and over the years, it has become a reputable resource for oncology professionals both within Canada and internationally. The journal encompasses a wide range of topics in cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation.
As Canada’s premier journal in this discipline, Current Oncology is indexed in multiple major databases, such as MEDLINE (PubMed/National Library of Medicine), the Science Citation Index Expanded (Web of Science), Journal Citation Reports, Scopus (Elsevier), and EMBASE (Elsevier), among others. With a 2019 Impact Factor of 2.257, the journal has established itself as a significant contributor to ongoing medical research and discourse in oncology.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The oncology sector in Canada has been evolving significantly in recent years, with research and advancements driving new treatments, therapies, and clinical practices. The need for high-quality, peer-reviewed publications in this criti
Similar Deals
Rogers Communications Inc. → Maple Leaf Sports and Entertainment
2025
ABC Technologies Holdings Inc. → WMG Technologies
2022
MDPI
invested in
Current Oncology
in 2020
in a Other deal